eISSN 1738-8872
pISSN 1017-7825
pISSN 1017-7825
Table. 1.
Table. 1.
List of candidate therapeutic agents for SARS-CoV-2 treatment.
| Candidate therapeutic | Market name | Manufacturer | Target disease | EC50(COVID-19) | Status of clinical trials |
|---|---|---|---|---|---|
| Favipiravir (T-705) | Avigan | Toyama | Influenza | 61.88 μM [41] | Under clinical trial for COVID-19 (ChiCTR2000029548) |
 |
|||||
| Remdesivir (GS-5734) |  |
Gilead | Ebola | 0.77 μM [41] | Phase II clinical trial for Ebola (NCT03719586); Under phase III clinical trials for COVID-19 (NCT04252664) |
| Chloroquine/Hydroxychloroquine | Aralen/Plaquenil | Sanofi | Malaria | 1.13 μM [41] | Under clinical trials for COVID-19 ( |
 |
|||||
| Lopinavir and Ritonavir | Kaletra | Abbott | HIV | − |
Under clinical trials for SARS [59] Under clinical trial for COVID-19 (ChiCTR2000029539) |
 |
|||||
| Pegylated interferon with ribavirin | Virazole | Valeant | HBV, HCV | 109 μM [41] | Under clinical trial for COVID-19 (ChiCTR2000029387) |
 |
aChiCTR2000029939, ChiCTR2000029935, ChiCTR2000029899, ChiCTR2000029898, ChiCTR2000029868, ChiCTR2000029837, ChiCTR2000029826, ChiCTR2000029803, ChiCTR2000029762, ChiCTR2000029761, ChiCTR2000029760, ChiCTR2000029740, ChiCTR2000029609, ChiCTR2000029559, and ChiCTR2000029542
bUndetermined
J. Microbiol. Biotechnol. 2020;30:313~324 https://doi.org/10.4014/jmb.2003.03011
© J. Microbiol. Biotechnol.